
Bristol Myers Squibb Advances Hodgkin Lymphoma Care Expanded Opdivo Approvals
Bristol Myers Squibb gains U.S. Food and Drug Administration and European Medicines Agency approvals, expanding Opdivo use in Hodgkin lymphoma Bristol Myers Squibb has announced significant regulatory milestones that mark a major advancement in the treatment landscape for classical Hodgkin…












